FDA Aims To Streamline Rules To Boost Development Of Biosimilar Drugs

FDA Aims To Streamline Rules To Boost Development Of Biosimilar Drugs According to the Food ​and Drug Administration, biologic medicines make up about 5% of prescriptions, ​yet they account for 51% of drug spending. Other FDA news is on a probe into rare-disease drug denials, flavored e-cigarettes, and more. https://kffhealthnews.org/morning-breakout/fda-aims-to-streamline-rules-to-boost-development-of-biosimilar-drugs/